| SSc-ILD | IPF | p-value | |
| Subjects n | 168 | 97 | |
| Age yrs | 49.5±13.2 | 63.7±8.8 | <0.00005 |
| Males/females n | 31/137 | 73/24 | <0.0005 |
| Never-/ex-smokers n | 108/60 | 17/80 | <0.0005 |
| Deaths | 60/168 (36) | 84/97 (87) | <0.0005 |
| 5-yr survival % | 76 | 18 | |
| Patients with FVC decline | 87/152 (57) | 63/89 (71) | <0.05 |
| Median time to decline months | 57 | 11 | |
| Patients with DL,CO decline | 88/152 (58) | 61/89 (69) | 0.10 |
| Median time to decline months | 62 | 11 | |
| Patients with PFS | 32/152 (21) | 6/89 (7) | <0.005 |
| Median time to decline months | 36 | 10 | |
| FVC % pred | 78.2±21.5 | 67.8±20.6 | <0.0005 |
| DL,CO % pred | 55.4±17.0 | 36.9±14.7 | <0.00005 |
| CPI | 39.8±15.4 | 55.0±13.7 | <0.00005 |
| HRCT disease extent % | 13.3 (1.0–84.0) | 56.5 (8.5–96.0) | <0.00005 |
Data are presented as mean±sd , n/N (%) or median (range), unless otherwise stated. SSc: systemic sclerosis; ILD: interstitidl lung disease; IPF: idiopathic pulmonary fibrosis; FVC: forced vital capacity; DL,CO: diffusing capacity of the lung for carbon monoxide; PFS: progression-free survival; % pred: % predicted; CPI: composite physiologic index; HRCT: high-resolution computed tomography.